{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab+IV&page=2", "query": { "intervention": "Ocrelizumab IV", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab+IV&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab+IV&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T01:06:24.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05123703", "title": "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Ocrelizumab Placebo", "type": "OTHER" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Fingolimod Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 188, "start_date": "2022-05-19", "completion_date": "2029-09-17", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 10, "location_summary": "La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123703" }, { "nct_id": "NCT02545868", "title": "A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "23-PPV", "type": "BIOLOGICAL" }, { "name": "13-PCV Booster", "type": "BIOLOGICAL" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "KLH", "type": "BIOLOGICAL" }, { "name": "OCR", "type": "DRUG" }, { "name": "TT Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 102, "start_date": "2015-10-27", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 20, "location_summary": "Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02545868" }, { "nct_id": "NCT04466150", "title": "Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Relapsing Multiple Sclerosis", "Clinically Isolated Syndrome" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 30, "start_date": "2020-08-30", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04466150" }, { "nct_id": "NCT03523858", "title": "A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Progressive Multiple Sclerosis (PMS)" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 927, "start_date": "2018-05-28", "completion_date": "2026-10-22", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 15, "location_summary": "Laguna Hills, California • Pasadena, California • San Francisco, California + 12 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03523858" }, { "nct_id": "NCT00476996", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 836, "start_date": "2007-05-15", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-08-12", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 144, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476996" }, { "nct_id": "NCT01194570", "title": "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 735, "start_date": "2011-03-02", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194570" }, { "nct_id": "NCT01412333", "title": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Ocrelizumab-matching placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interferon beta-1a-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 835, "start_date": "2011-09-20", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01412333" }, { "nct_id": "NCT05285891", "title": "Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo for Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 123, "start_date": "2023-02-07", "completion_date": "2032-02-25", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 13, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05285891" }, { "nct_id": "NCT02980042", "title": "Safety of Switching From Rituximab to Ocrelizumab in MS Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 200, "start_date": "2017-01-01", "completion_date": "2019-03-06", "has_results": true, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02980042" }, { "nct_id": "NCT02688985", "title": "Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerorsis", "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methyloprednisolone", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 131, "start_date": "2016-04-29", "completion_date": "2023-04-11", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-06T01:06:24.891Z", "location_count": 12, "location_summary": "Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688985" } ] }